The prognosis for patients diagnosed with epithelial ovarian cancer remains poor, especially in those patients resistant to platinum therapy. Evidence has suggested that the Wee1 inhibitor adavosertib may be efficacious in combination with chemotherapy. Moore and colleagues conducted a clinical trial of adavosertib combined with four commonly used chemotherapeutics in patients with primary platinum-resistant ovarian cancer. Combinations were effective, with 3% of patients achieving a complete response and 29% of patients with partial response. The response rate was highest with adavosertib plus carboplatin, while the longest duration of response was observed in patients treated with adavosertib plus paclitaxel. However, many patients experienced toxicity. These results indicate that although adavosertib may have promise for the treatment of ovarian cancer, further clinical study is necessary to minimize toxicity.

Checkpoint inhibitors have improved outcomes in patients with many cancer subtypes, but resistance to treatment remains a challenge. In this clinical trial, Siu and...

You do not currently have access to this content.